BFC
BIOC

Bedel Financial Consulting’s Biocept, Inc. BIOC Stock Holding History

Bedel Financial Consulting’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67
Closed -$14K – 869
2020
Q2 		$14K Buy
+67
New +$9.61K 0.01% 447

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $434M AUM 19.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bedel Financial Consulting's BIOC Position: Q3 2020 in Review

Bedel Financial Consulting sold out of Biocept, Inc. (BIOC) in Q3 2020, closing a stake of 67 shares — an estimated $14K sold.

Bedel Financial Consulting first reported a position in BIOC in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 18 funds tracked by Wall St. Rank hold BIOC as of Q3 2020.

  • Bedel Financial Consulting reported no remaining Biocept, Inc. position as of Q3 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 67 Biocept, Inc. shares in Q3 2020, an estimated $14K.
  • Bedel Financial Consulting first reported a position in Biocept, Inc. in Q2 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's Biocept, Inc. position peaked at $14K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2020.

Based on Bedel Financial Consulting's 13F filing for Q3 2020, filed 20 Oct 2020.